Secretory Leukocyte Protease Inhibitor Suppresses the Inflammation and Joint Damage of Bacterial Cell Wall-Induced Arthritis

doi:10.1084/jem.190.4.535

This Article

	Full Text
	Full Text (PDF, 312K)
	PPT slides of all figures
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Song, X.-y.
	Articles by Wahl, S. M.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Song, X.-y.
	Articles by Wahl, S. M.


Social Bookmarking

	What's this?

© The Rockefeller University Press, 0022-1007/1999/8/535/ $5.00
The Journal of Experimental Medicine, Volume 190, Number 4, August 16, 1999 535-542

Original Article

Secretory Leukocyte Protease Inhibitor Suppresses the Inflammation and Joint Damage of Bacterial Cell Wall–Induced Arthritis

Xiao-yu Song^a, Li Zeng^a, Wenwen Jin^a, John Thompson^a, Diane E. Mizel^a, Ke-jian Lei^a, R.C. Billinghurst^b, A. Robin Poole^b, and Sharon M. Wahl^a

^a From the Oral Infection and Immunity Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland 20892-4352
^b Joint Diseases Laboratory, Shriners Hospitals for Children, Division of Surgical Research, Department of Surgery, McGill University, Montreal, Canada, H3G1A6
Oral Infection and Immunity Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bldg. 30, Rm. 332, 30 Convent Dr., MSC 4352, Bethesda, MD 20892-4352.301-402-1064301-496-4178

smwahl{at}dir.nidcr.nih.gov

Disruption of the balance between proteases and protease inhibitorsis often associated with pathologic tissue destruction. To explorethe therapeutic potential of secretory leukocyte protease inhibitor(SLPI) in erosive joint diseases, we cloned, sequenced, andexpressed active rat SLPI, which shares the protease-reactivesite found in human SLPI. In a rat streptococcal cell wall (SCW)-inducedmodel of inflammatory erosive polyarthritis, endogenous SLPIwas unexpectedly upregulated at both mRNA and protein levelsin inflamed joint tissues. Systemic delivery of purified recombinantrat SLPI inhibited joint inflammation and cartilage and bonedestruction. Inflammatory pathways as reflected by circulatingtumor necrosis factor ${alpha}$ and nuclear factor ${kappa}$ B activation and cartilageresorption detected by circulating levels of type II collagencollagenase-generated cleavage products were all diminishedby SLPI treatment in acute and chronic arthritis, indicatingthat the action of SLPI may extend beyond inhibition of serineproteases.

Key Words: inflammation • cartilage resorption • serine protease inhibitor

1used in this paper: AI, severity of arthritis; NF, nuclearfactor; PM, peritoneal macrophage; SCW, streptococcal cell wall;SLPI, secretory leukocyte protease inhibitor

Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Facebook Add to Reddit Reddit Add to Technorati Technorati Twitter What's this?

This article has been cited by other articles:

Ghasemlou, N., Bouhy, D., Yang, J., Lopez-Vales, R., Haber, M., Thuraisingam, T., He, G., Radzioch, D., Ding, A., David, S. (2010). Beneficial effects of secretory leukocyte protease inhibitor after spinal cord injury. Brain 133: 126-138 [Abstract] [Full Text]
Fakioglu, E., Wilson, S. S., Mesquita, P. M. M., Hazrati, E., Cheshenko, N., Blaho, J. A., Herold, B. C. (2008). Herpes Simplex Virus Downregulates Secretory Leukocyte Protease Inhibitor: a Novel Immune Evasion Mechanism. J. Virol. 82: 9337-9344 [Abstract] [Full Text]
Jacobsen, L. C., Sorensen, O. E., Cowland, J. B., Borregaard, N., Theilgaard-Monch, K. (2008). The secretory leukocyte protease inhibitor (SLPI) and the secondary granule protein lactoferrin are synthesized in myelocytes, colocalize in subcellular fractions of neutrophils, and are coreleased by activated neutrophils. J. Leukoc. Biol. 83: 1155-1164 [Abstract] [Full Text]
Wahl, S. M., Greenwell-Wild, T., Vazquez, N. (2006). HIV accomplices and adversaries in macrophage infection. J. Leukoc. Biol. 80: 973-983 [Abstract] [Full Text]
Beynnon, B. D., Uh, B. S., Johnson, R. J., Abate, J. A., Nichols, C. E., Fleming, B. C., Poole, A. R., Roos, H. (2005). Rehabilitation After Anterior Cruciate Ligament Reconstruction: A Prospective, Randomized, Double-Blind Comparison of Programs Administered Over 2 Different Time Intervals. Am J Sports Med 33: 347-359 [Abstract] [Full Text]
Velarde, M C, Parisek, S I, Eason, R R, Simmen, F A, Simmen, R C M (2005). The secretory leukocyte protease inhibitor gene is a target of epidermal growth factor receptor action in endometrial epithelial cells. J Endocrinol 184: 141-151 [Abstract] [Full Text]
Schulze, H., Korpal, M., Bergmeier, W., Italiano, J. E. Jr, Wahl, S. M., Shivdasani, R. A. (2004). Interactions between the megakaryocyte/platelet-specific {beta}1 tubulin and the secretory leukocyte protease inhibitor SLPI suggest a role for regulated proteolysis in platelet functions. Blood 104: 3949-3957 [Abstract] [Full Text]
Ma, G., Greenwell-Wild, T., Lei, K., Jin, W., Swisher, J., Hardegen, N., Wild, C. T., Wahl, S. M. (2004). Secretory Leukocyte Protease Inhibitor Binds to Annexin II, a Cofactor for Macrophage HIV-1 Infection. JEM 200: 1337-1346 [Abstract] [Full Text]
Greene, C. M., McElvaney, N. G., O'Neill, S. J., Taggart, C. C. (2004). Secretory Leucoprotease Inhibitor Impairs Toll-Like Receptor 2- and 4-Mediated Responses in Monocytic Cells. Infect. Immun. 72: 3684-3687 [Abstract] [Full Text]
Wahl, S. M., Greenwell-Wild, T., Peng, G., Ma, G., Orenstein, J. M., Vazquez, N. (2003). Viral and host cofactors facilitate HIV-1 replication in macrophages. J. Leukoc. Biol. 74: 726-735 [Abstract] [Full Text]
Wang, X., Li, X., Xu, L., Zhan, Y., Yaish-Ohad, S., Erhardt, J. A., Barone, F. C., Feuerstein, G. Z. (2003). Up-Regulation of Secretory Leukocyte Protease Inhibitor (SLPI) in the Brain after Ischemic Stroke: Adenoviral Expression of SLPI Protects Brain from Ischemic Injury. Mol. Pharmacol. 64: 833-840 [Abstract] [Full Text]
Odaka, C., Mizuochi, T., Yang, J., Ding, A. (2003). Murine Macrophages Produce Secretory Leukocyte Protease Inhibitor During Clearance of Apoptotic Cells: Implications for Resolution of the Inflammatory Response. J. Immunol. 171: 1507-1514 [Abstract] [Full Text]
Devoogdt, N., Hassanzadeh Ghassabeh, G., Zhang, J., Brys, L., De Baetselier, P., Revets, H. (2003). Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proc. Natl. Acad. Sci. USA 100: 5778-5782 [Abstract] [Full Text]
Nakamura, A., Mori, Y., Hagiwara, K., Suzuki, T., Sakakibara, T., Kikuchi, T., Igarashi, T., Ebina, M., Abe, T., Miyazaki, J., Takai, T., Nukiwa, T. (2003). Increased Susceptibility to LPS-induced Endotoxin Shock in Secretory Leukoprotease Inhibitor (SLPI)-deficient Mice. JEM 197: 669-674 [Abstract] [Full Text]
Hagiwara, K., Kikuchi, T., Endo, Y., Huqun, , Usui, K., Takahashi, M., Shibata, N., Kusakabe, T., Xin, H., Hoshi, S., Miki, M., Inooka, N., Tokue, Y., Nukiwa, T. (2003). Mouse SWAM1 and SWAM2 Are Antibacterial Proteins Composed of a Single Whey Acidic Protein Motif. J. Immunol. 170: 1973-1979 [Abstract] [Full Text]
Poole, A R, Kobayashi, M, Yasuda, T, Laverty, S, Mwale, F, Kojima, T, Sakai, T, Wahl, C, El-Maadawy, S, Webb, G, Tchetina, E, Wu, W (2002). Type II collagen degradation and its regulation in articular cartilage in osteoarthritis. Ann Rheum Dis 61: ii78-81 [Full Text]
Zhang, D., Simmen, R. C. M., Michel, F. J., Zhao, G., Vale-Cruz, D., Simmen, F. A. (2002). Secretory Leukocyte Protease Inhibitor Mediates Proliferation of Human Endometrial Epithelial Cells by Positive and Negative Regulation of Growth-associated Genes. J. Biol. Chem. 277: 29999-30009 [Abstract] [Full Text]
Jorgensen, C, Noel, D, Apparailly, F, Sany, J (2001). Stem cells for repair of cartilage and bone: the next challenge in osteoarthritis and rheumatoid arthritis. Ann Rheum Dis 60: 305-309 [Full Text]